The stock of Novo Nordisk A S (ADR) (NYSE:NVO) hit a new 52-week low and has $31.01 target or 6.00% below today’s $32.99 share price. The 6 months bearish chart indicates high risk for the $65.59 billion company. The 1-year low was reported on Nov, 14 by Barchart.com. If the $31.01 price target is reached, the company will be worth $3.94B less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. About 3.46M shares traded hands. Novo Nordisk A S (ADR) (NYSE:NVO) has declined 40.17% since April 12, 2016 and is downtrending. It has underperformed by 45.15% the S&P500.
Novo Nordisk A S (ADR) (NYSE:NVO) Ratings Coverage
Out of 13 analysts covering Novo Nordisk (ADR) (NYSE:NVO), 3 rate it a “Buy”, 2 “Sell”, while 8 “Hold”. This means 23% are positive. Novo Nordisk (ADR) has been the topic of 13 analyst reports since August 28, 2015 according to StockzIntelligence Inc. The rating was downgraded by UBS on Monday, February 8 to “Sell”. The stock of Novo Nordisk A S (ADR) (NYSE:NVO) earned “Market Perform” rating by Leerink Swann on Friday, August 28. Zacks upgraded the shares of NVO in a report on Friday, August 28 to “Hold” rating. The stock has “Neutral” rating given by JP Morgan on Friday, September 9. The company was downgraded on Monday, October 31 by DNB Markets. The rating was upgraded by Goldman Sachs to “Conviction Buy” on Monday, February 15. The firm has “Outperform” rating by BNP Paribas given on Tuesday, September 13. The firm has “Underperform” rating by Bank of America given on Friday, October 28. As per Friday, September 23, the company rating was initiated by Piper Jaffray. The stock has “Strong Buy” rating given by Jyske Bank on Monday, October 19.
According to Zacks Investment Research, “Novo Nordisk is a world leader in insulin and diabetes care and also manufactures and markets a variety of other pharmaceutical products. Furthermore the company is the world’s largest producer of industrial enzyme products. The company believes that everyone must care for the environment and our natural resources.”
More news for Novo Nordisk A S (ADR) (NYSE:NVO) were recently published by: Marketwatch.com, which released: “Virtual Stock Exchange” on July 03, 2009. Quotes.Wsj.com‘s article titled: “DOW JONES, A NEWS CORP COMPANY” and published on February 11, 2011 is yet another important article.
NVO Company Profile
Novo Nordisk A/S, incorporated on November 28, 1931, is a healthcare company. The Firm is engaged in discovery, development, manufacturing and marketing of pharmaceutical products. The Company’s business divisions include diabetes and obesity care, and biopharmaceuticals. The diabetes and obesity care segment covers insulins, glucagon-like peptide-1 (GLP-1), other protein-related products (such as glucagon, protein-related delivery systems and needles), oral anti-diabetic drugs and obesity. The biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.